Compare Inovio Pharmaceuticals Inc (INO) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Main Street Capital Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Main Street Capital Corporation trades at $54.6 (market cap $5.08B). The key difference: Main Street Capital Corporation is far larger — about 56.9× Inovio Pharmaceuticals Inc's market cap, and Main Street Capital Corporation pays a 8.02% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MAIN | |
|---|---|---|
Market Cap | $89.27M | $5.08B |
Sector | Health | Financials |
52-Week High | $2.87 | $67.54 |
52-Week Low | $1.05 | $49.63 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 8.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Main Street Capital (MAIN) trades at $54.19, down 2.13% today, with a bullish technical signal from moving averages. The stock shows strong profitability with an 81.08% net income margin and a P/E of 11.49, below industry averages. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains a consistent dividend history, with recent payouts of $0.27-$0.30 per share, supporting income-focused investors.
Outlook remains cautious with 78.57% of analysts rating Hold, citing potential earnings softness. The consensus price target is $57.75, offering modest upside. Key risks include declining revenue projections for 2026 and negative operating cash flow. MAIN's premium valuation relative to book value is justified by cost advantages, but investors should monitor earnings sustainability amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
